<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04283227</url>
  </required_header>
  <id_info>
    <org_study_id>OTL-200-07</org_study_id>
    <nct_id>NCT04283227</nct_id>
  </id_info>
  <brief_title>OTL-200 in Patients With Late Juvenile Metachromatic Leukodystrophy (MLD)</brief_title>
  <official_title>An Open Label, Non-randomized Trial to Evaluate the Safety and Efficacy of a Single Infusion of OTL-200 in Patients With Late Juvenile (LJ) Metachromatic Leukodystrophy (MLD).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orchard Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ospedale San Raffaele</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Orchard Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      OTL-200 is a cryopreserved dispersion for infusion containing autologous CD34+ cell enriched&#xD;
      population that contains haematopoietic stem and progenitor cells (HSPC) transduced ex vivo&#xD;
      using a lentiviral vector encoding the human arylsulfatase A (ARSA) gene. MLD is an autosomal&#xD;
      recessive lysosomal storage disorder (LSD) characterized by severe and progressive&#xD;
      demyelination affecting the central and peripheral nervous system. The aim of this clinical&#xD;
      study is to assess the pharmacodynamic effect and long-term clinical efficacy and safety of&#xD;
      OTL-200 in Late Juvenile MLD patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 31, 2020</start_date>
  <completion_date type="Anticipated">January 2032</completion_date>
  <primary_completion_date type="Anticipated">January 2032</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All eligible subjects will receive intravenous (IV) infusion of OTL-200 gene therapy. Subjects will also receive conditioning regimen with busulfan.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in ARSA activity levels in Cerebrospinal Fluid (CSF)</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in neuronal metabolite ratio of N-acetyl-aspartate (NAA) to creatine (Cr) in white matter regions of the brain</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Lysosomal Storage Diseases</condition>
  <condition>Metachromatic Leukodystrophy</condition>
  <arm_group>
    <arm_group_label>OTL-200 Gene Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OTL-200 is an autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells (HSPC) transduced ex vivo using a lentiviral vector encoding the human arylsulfatase A (ARSA) gene.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>OTL-200</intervention_name>
    <description>All subjects will receive OTL-200 gene therapy and will be followed up for 8 years following treatment with OTL-200.</description>
    <arm_group_label>OTL-200 Gene Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All the following criteria need to be met:&#xD;
&#xD;
          -  Documented biochemical and molecular diagnosis of MLD, based on ARSA activity below&#xD;
             the normal range and identification of two disease-causing ARSA alleles.&#xD;
&#xD;
          -  0/R or R/R genotype or a genotype recognized as associated with the LJ variant of MLD.&#xD;
&#xD;
          -  a) If symptomatic: age at disease onset between ≥7 and &lt;17 years of age (i.e. before&#xD;
             their 17th birthday). OR&#xD;
&#xD;
          -  b) If pre-symptomatic: participant must be &lt;17 years of age at treatment (i.e. before&#xD;
             their 17th birthday) AND must have a sibling with a diagnosis of late-juvenile MLD&#xD;
             variant based on age at disease onset (≥7 and &lt;17 years of age i.e. before sibling's&#xD;
             17th birthday), with biochemical and molecular diagnosis.&#xD;
&#xD;
          -  Normal cognitive function as defined by an IQ≥85 on age appropriate cognitive scales.&#xD;
&#xD;
          -  a) If the participant is &lt;7 years (i.e. before their 7th birthday): normal motor&#xD;
             milestones achievement, normal gross motor function according to chronological age and&#xD;
             normal neurological examination (if applicable based on the age of the subject,&#xD;
             GMFC-MLD = 0) OR b) If participant is ≥7 years: normal gross motor function or mild&#xD;
             gross motor function impairment, defined by a GMFC-MLD 0 or 1 (i.e. patient is able to&#xD;
             walk independently).&#xD;
&#xD;
          -  If applicable, participant willing and capable of compliance with contraceptive use&#xD;
             requirements.&#xD;
&#xD;
          -  Participant (or if applicable, parent/legal guardian) providing signed informed&#xD;
             consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Documented HIV infection (positive HIV RNA and/or anti-p24 antibodies).&#xD;
&#xD;
          -  Malignant neoplasia (except localised skin cancer) or a documented history of&#xD;
             hereditary cancer syndrome&#xD;
&#xD;
          -  Myelodysplasia, cytogenetic alterations characteristic of myelodysplastic syndrome&#xD;
             (MDS) and acute myeloid leukaemia (AML) or other serious haematological disorders.&#xD;
&#xD;
          -  Patients currently enrolled in other interventional trials&#xD;
&#xD;
          -  Has previously undergone allogeneic HSPC gene therapy (HSPC-GT) and has evidence of&#xD;
             residual cells of donor origin.&#xD;
&#xD;
          -  Previous gene therapy.&#xD;
&#xD;
          -  Has symptomatic herpes zoster, not responsive to specific treatment.&#xD;
&#xD;
          -  Evidence of active tuberculosis (TB) based upon medical examination, chest imaging and&#xD;
             TB testing&#xD;
&#xD;
          -  Acute or chronic stable Hepatitis B (HBV) as evidenced by positive Hepatitis B surface&#xD;
             antigen (HBsAg) test result at screening or within 3 months prior to onset of&#xD;
             conditioning and/or positive HBV DNA&#xD;
&#xD;
          -  Presence of positive Hepatitis C RNA test result at screening&#xD;
&#xD;
          -  End-organ dysfunction, severe active infection not responsive to treatment, or other&#xD;
             severe disease or clinical condition which, in the judgment of the investigator, would&#xD;
             make the participant inappropriate for entry into this study.&#xD;
&#xD;
          -  In addition to the potential infections tested per protocol, the PI should consider&#xD;
             testing for other transmissible infectious agents listed in the European Union (EU)&#xD;
             Cell and Tissue Directive as clinically appropriate and results must be discussed with&#xD;
             the Orchard medical monitor prior to stem cell harvest.&#xD;
&#xD;
          -  Participants with alanine transferase (ALT) &gt;2x upper limit of normal (ULN) or total&#xD;
             bilirubin &gt;1.5xULN may be included only after discussed and agreed with the Orchard&#xD;
             medical monitor and considered in the context of the criterion for excluding&#xD;
             participants with other severe disease. Isolated elevation of total bilirubin &gt;1.5xULN&#xD;
             is acceptable if bilirubin is fractionated and direct bilirubin &lt;35% of total.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Orchard Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Orchard Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Orchard Clinical Trials</last_name>
    <phone>+44 (0) 20 3808 8286</phone>
    <email>medinfo@orchard-tx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Orchard Clinical Trials</last_name>
    <email>medinfo@orchard-tx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ospedale San Raffaele - Telethon Institute for Gene Therapy (OSR-TIGET)</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Fumagalli</last_name>
      <phone>+39 0226434472</phone>
      <email>fumagalli.francesca@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Francesca Fumagalli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 13, 2020</study_first_submitted>
  <study_first_submitted_qc>February 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2020</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OTL-200</keyword>
  <keyword>Cryopreserved formulation</keyword>
  <keyword>Gene therapy</keyword>
  <keyword>MLD</keyword>
  <keyword>late juvenile</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukodystrophy, Metachromatic</mesh_term>
    <mesh_term>Lysosomal Storage Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

